Completed PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT01959633

Vemurafenib Plus Cobimetinib Plus PEG-interferon in Advanced Melanoma Patients Harboring the V600BRAF Mutation (VEMUPLINT)

Phase I-II Study of the Combination Vemurafenib Plus Cobimetinib Plus PEG-interferon in Advanced Melanoma Patients Harboring the V600BRAF Mutation

Sponsor: Fondazione Melanoma Onlus

Conditions Melanoma

Interventions Cobimetinib Peg-interferon Vemurafenib

Updated 8 times since 2017 Last updated: Feb 23, 2022 Started: Apr 3, 2014 Primary completion: Mar 26, 2018 Completion: Mar 26, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Melanoma and is currently completed. Fondazione Melanoma Onlus leads this study, which shows 8 recorded versions since 2014 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Mar 2022 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Jan 2021 — Mar 2022 [monthly]

Completed PHASE1_PHASE2
Jul 2019 — Jan 2021 [monthly]

Completed PHASE1_PHASE2

Status: Unknown Status → Completed

▶ Show 3 earlier versions

Feb 2019 — Jul 2019 [monthly]

Unknown Status PHASE1_PHASE2

Status: Recruiting → Unknown Status
Jun 2018 — Feb 2019 [monthly]

Recruiting PHASE1_PHASE2
Jan 2017 — Jun 2018 [monthly]

Recruiting PHASE1_PHASE2

First recorded

Apr 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Fondazione Melanoma Onlus

Data source: Fondazione Melanoma Onlus

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Napoli, Italy